CRXM
$0.04
Cardium Therapeutics Inc Comm
$.01
25.00%
CRXM
Earnings Whisper ®
N/A
Consensus:  $0.00
Revenue:  N/A
Friday
Dec 11
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS

What do you expect when CRXM reports earnings?
Beat
Meet
Miss

Where is CRXM's stock price going from here?
Up
Flat
Down
Stock chart of CRXM
Analysts
Summary of analysts' recommendations for CRXM
Score
Grade
Pivots
Resistance
$0.04
$0.03
$0.03

$0.03

Support
$0.03
$0.03
$0.02
Tweet
Growth
Description
Taxus Cardium Pharmaceuticals Group Inc. operates as a development stage advanced regenerative therapeutics company. It is focused on the late-stage clinical and commercial development of regenerative medicine therapeutics. The company provides Generx (R) for the treatment of cardiac microvascular insufficiency due to advancing coronary artery disease, and Excellagen (R), for the treatment of chronic non-healing diabetic foot, venous and pressure ulcers. Taxus Cardium Pharmaceuticals Group Inc., formerly known as Cardium Therapeutics, Inc., is headquartered in San Diego, California.